Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLX 105

Next Previous
Drug Profile

CLX 105

Alternative Names: CLX-105

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellix Bio
  • Class Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action GABA uptake inhibitors; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Epilepsy

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for preclinical development in Epilepsy in India
  • 20 Feb 2018 Cellixbio has patent protection and pending patent applications for compositions and methods for the treatment of epilepsy and neurological diseases in USA, before February 2018 (Cellixbio pipeline, February 2018)
  • 20 Feb 2018 Preclinical trials in Epilepsy in India (unspecified route) (Cellixbio pipeline, February 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top